Past Press Releases

Oragenics, Inc. Receives Notification Letter From American Stock Exchange, posted 04.30.07

Oragenics Wins Phase 1 SBIR Grant for Colorectal Cancer Study, posted 04.05.07

President’s Letter to Shareholders, posted 02.13.07

Oragenics Announces the Exercise of All Outstanding Warrants from December 2005 Private Financing Round, posted 01.19.07

Oragenics Calls Outstanding Warrants from December 2005 Private Financing Round, posted 12.12.06

Oragenics Seeks Patent for Unique Gene Targets for Tuberculosis, posted 12.07.06

Oragenics Finalizes Acquisition of the iviGene Corporation, posted 11.27.06

Oragenics to Pursue Licensing of its’ Oral Probiotic Mouthrinse Following Positive Clinical Results, posted 11.15.06

Oragenics Reports Positive Clinical Results with its Oral Probiotic Mouthrinse, posted 10.19.06

Oragenics’ Lead Antibiotic Kills Bacteria by a Novel Mechanism, posted 09.19.06

Oragenics Announces Fourth U.S. Patent Issued for MU1140™, posted 08.09.06

Four Dental Experts Join Oragenics’ International Scientific Advisory Board, posted 07.17.06

Oragenics Receives $600,000 from Exercised Warrants, posted 07.06.06

Oragenics To Enter Clinic with its Oral Probiotic Mouthrinse, posted 06.14.06

Oragenics to Present at the Dutton Associates’ Health Sciences Small Cap Conference, posted 05.24.06

Oragenics' Lead Antibiotic Proves Effective in Animal Infection Model, posted 05.16.06

Oragenics Receives SBIR Grant, Seeks Patent for Novel Synthetic Chemistry Technology, posted 05.03.06

Oragenics Seeks Patent for Novel Agent to Treat Obesity, posted 04.05.06

Oragenics Completes $600,000 Financing, posted 03.10.06

President’s Letter to Shareholders, posted 02.25.06

Oragenics Announces Financing Commitment of $600,000, posted 01.11.06

Dr. Raman Bedi joins Oragenics as Senior Consultant, posted 01.11.06

Oragenics Completes $1.175 Million Financing , posted 12.19.05

Oragenics Announces Financing Commitment, posted 11.22.05

Oragenics Names Robert Zahradnik as President, CEO, posted 09.13.05

Oragenics, Inc. Retains New Auditors and Transfer Agent, posted 08.30.05

Oragenics, Inc. Appoints Investor Awareness, Inc. To Launch Investor Relations Program, posted 08.23.05

Webcast Alert: Oragenics at Informed Investors Thursday, August 25, 2005, 10:30am ET, posted 08.18.05

Oragenics Reports Second Quarter 2005 Results and Development Progress, posted 08.11.05

Oragenics Names New Interim Chief Executive Officer, posted 07.07.05

Oragenics Enters Agreement to Obtain up to $9 Million in Equity Financing, posted 05.25.05

Oragenics Initiates Phase I Safety Study of Novel Treatment For Preventing Tooth Decay, posted 05.02.05

President’s Letter to Shareholders - April '05, posted 04.21.05

Oragenics Announces Successful Manufacturing of Novel Antibiotic, posted 04.04.05

Oragenics Announces 2004 Financial Results and Files Annual Report, posted 03.17.05

President’s Letter to Shareholders - Feb. '05, posted 02.07.05

David Gury Elected Chairman of Oragenics, posted 12.09.04

FDA Lifts Clinical Hold on Novel Treatment for Prevention of Dental Caries, posted 12.01.04

Oragenics Announces First Closing on Private Placement , posted 12.01.04

James W. Sharpe Named VP Business Development, posted 11.11.04

Start-Up: Windhover's Review of Emerging Medical Ventures, posted 11.03.04

Replacement Therapy Technology on Clinical Hold, posted 10.26.04

Oragenics at Rodman & Renshaw Techvest, Oct 26-28, posted 10.15.04

Edmund Mickunas Named VP Regulatory & Clinical Affairs, posted 10.01.04

Oragenics to Present at BIO, posted 09.22.04

Oragenics Approved For AMEX Listing, posted 05.13.04

Oragenics Warrants Exercised, posted 03.25.04

Oragenics Receives Unanimous RAC Recommendation , posted 03.14.04

Oragenics Licenses Novel Technology, posted 03.03.04

Oragenics Breaks Ground for New Headquarters, posted 02.17.04

Eric Chojnick Appointed VP Product Development, posted 02.01.04

Oragenics Accepted on OTCBB Registry, posted 01.21.04

Oragenics Receives $2.4 Million Through Warrant Exercise, posted 01.04.04

New Board Member Named, posted 10.01.03

Oragenics Files For U.S. Patent, posted 08.13.03

Oragenics Completes Initial Public Offering, posted 06.23.03

About Oragenics | Product Portfolio | Press Room | Investor Relations | Contact Us | Copyright Oragenics | Design by